N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase
Open Access
- 8 November 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 93 (1), 120-129
- https://doi.org/10.1093/cvr/cvr267
Abstract
The mammalian soluble epoxide hydrolase (sEH) has both an epoxide hydrolase and a phosphatase domain. The role of sEH hydrolase activity in the metabolism of epoxyeicosatrienoic acids (EETs) and the activation of endothelial nitric oxide synthase (eNOS) in endothelial cells (ECs) has been well defined. However, far less is known about the role of sEH phosphatase activity in eNOS activation. In the present study, we investigated whether the phosphatase domain of sEH was involved in the eNOS activation in ECs. The level of eNOS phosphorylation in aortas is higher in the sEH knockout (sEH−/−) mice than in wild-type mice. In ECs, pharmacological inhibition of sEH phosphatase or overexpressing sEH with an inactive phosphatase domain enhanced vascular endothelial growth factor (VEGF)-induced NO production and eNOS phosphorylation. In contrast, overexpressing the phosphatase domain of sEH prevented the VEGF-mediated NO production and eNOS phosphorylation at Ser617, Ser635, and Ser1179. Additionally, treatment with VEGF induced a c-Src kinase-dependent increase in transient tyrosine phosphorylation of sEH and the formation of a sEH–eNOS complex, which was abolished by treatment with a c-Src kinase inhibitor, PP1, or the c-Src dominant-negative mutant K298M. We also demonstrated that the phosphatase domain of sEH played a key role in VEGF-induced angiogenesis by detecting the tube formation in ECs and neovascularization in Matrigel plugs in mice. In addition to epoxide hydrolase activity, phosphatase activity of sEH plays a pivotal role in the regulation of eNOS activity and NO-mediated EC functions.Keywords
This publication has 39 references indexed in Scilit:
- Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibitionCardiovascular Research, 2009
- Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitrationJCI Insight, 2009
- Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophyProceedings of the National Academy of Sciences, 2009
- An Ezrin/Calpain/PI3K/AMPK/eNOSs1179Signaling Cascade Mediating VEGF-Dependent Endothelial Nitric Oxide ProductionCirculation Research, 2009
- Soluble epoxide hydrolase and epoxyeicosatrienoic acids modulate two distinct analgesic pathwaysProceedings of the National Academy of Sciences of the United States of America, 2008
- Soluble Epoxide Hydrolase Inhibitors Reduce the Development of Atherosclerosis in Apolipoprotein E-Knockout Mouse ModelJournal of Cardiovascular Pharmacology, 2008
- Functional Role of HSP90 Complexes with Endothelial Nitric-oxide Synthase (eNOS) and Calpain on Nitric Oxide Generation in Endothelial CellsJournal of Biological Chemistry, 2008
- Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7Proceedings of the National Academy of Sciences, 2008
- Src-mediated Phosphorylation of Hsp90 in Response to Vascular Endothelial Growth Factor (VEGF) Is Required for VEGF Receptor-2 Signaling to Endothelial NO SynthaseMolecular Biology of the Cell, 2007
- Life history of eNOS: Partners and pathwaysCardiovascular Research, 2007